Derivation of no significant risk levels for three lower acrylates: Conclusions and recommendations from an expert panel

C.R. Kirman*, P.J. Boogaard, J.S. Bus, V.L. Dellarco, K. Shao, B.R. Stern, S.M. Hays

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A panel of toxicology, mode of action (MOA), and cancer risk assessment experts was engaged to derive no-significant-risk-levels (NSRLs) for three lower acrylates: methyl acrylate (MA), ethyl acrylate (EA), and 2-ethylhexyl acrylate (2EHA) using the best available science, data, and methods. The review was structured as a five-round, modified Delphi format, a systematic process for collecting independent and deliberative input from panel members, and it included several procedural elements to reduce potential sources of bias and groupthink. Input from the panel for key decisions in the dose-response assessments resulted in NSRL values of 530 μg/day (330–800 μg/day), 640 μg/day (280–670 μg/day), and 1700 μg/day (1300–2700 μg/day) for MA, EA, and 2EHA, respectively. Novel to this approach were the use of nonneoplastic lesions reported at point of contact where tumors have been reported in laboratory rodents, along with nonlinear extrapolation to low doses (uncertainty factor approach) based upon panel recommendations. Confidence in these values is considered medium to high for exposures applied to the routes of exposure tested (inhalation for MA and EA, dermal for 2EHA), but confidence is considered lower when applied to other routes of exposure.

Original languageEnglish
Article number105567
JournalRegulatory Toxicology and Pharmacology
Volume148
DOIs
Publication statusPublished - Mar 2024

Keywords

  • Benchmark dose
  • Expert panel
  • Mode of action
  • Nonlinear dose-response
  • NSRL

Fingerprint

Dive into the research topics of 'Derivation of no significant risk levels for three lower acrylates: Conclusions and recommendations from an expert panel'. Together they form a unique fingerprint.

Cite this